Biodexa Pharmaceuticals (BDRX) Return on Capital Employed (2016 - 2025)

Biodexa Pharmaceuticals (BDRX) posted Return on Capital Employed of 157.97% for Q2 2025, up 23.52% sequentially from 206.54% in Q4 2024.

Biodexa Pharmaceuticals (BDRX) Return on Capital Employed (2016 - 2025) Analysis & Trends

Biodexa Pharmaceuticals has reported Return on Capital Employed for 6 years, with the latest figure at 157.97% in Q2 2025.

Quarterly Return on Capital Employed changed N/A year-over-year to 157.97% in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 157.97% (changed N/A YoY) and the FY2025 annual result came in at 85.14%, up 3811.0% from the prior year.
Return on Capital Employed improved to 157.97% in Q2 2025 per BDRX's latest filing, from 206.54% in the prior quarter.
Over five years, Return on Capital Employed peaked at 157.97% in Q2 2025 and troughed at 513.99% in Q4 2023.
A 3-year average of 307.11% and a median of 278.23% in 2023 frame the typical range for Return on Capital Employed.
The widest YoY moves for Return on Capital Employed: up 30746 bps in 2024, down 30746 bps in 2024.
Over 3 years, Return on Capital Employed stood at 513.99% in 2023, then jumped by 60 bps to 206.54% in 2024, then grew by 24 bps to 157.97% in 2025.
According to Business Quant data, Return on Capital Employed over the past three periods registered 157.97%, 206.54%, and 513.99% for Q2 2025, Q4 2024, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	20.76%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	10.74%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-38.20%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	13.68%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	26.09%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-6.85%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-50.93%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	7.88%
10	Biodexa Pharmaceuticals	64,325.41	-11.29 Mn	-	-

Download Data